(41) also underlined the complementary value of GRPR targeting as they identified 7 additional lesions with [68Ga]Ga-RM2 (a potent GRPR-targeting agent) PET that were not visible on [68Ga]Ga-PSMA11/[18F]F-DCFPyL PET in 4/50 biochemically recurrent PCa patients. This evidence concerns the gene GRPR and posterior cortical atrophy.